Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Ascelia Pharma AB ( (SE:ACE) ).
Ascelia Pharma has announced that Deputy CEO and CFO Julie Waras Brogren will leave the company to assume a CEO role elsewhere, after playing a key role in advancing the commercial strategy, partnering efforts and financial function, particularly around the late‑stage development and regulatory progression of its lead drug candidate Orviglance. She will remain with the company to ensure a smooth transition of responsibilities and to support the onboarding of incoming CFO Anton Hansson, limiting operational disruption during an important phase for Ascelia Pharma’s pipeline and its positioning in the orphan oncology market.
The most recent analyst rating on (SE:ACE) stock is a Hold with a SEK3.00 price target. To see the full list of analyst forecasts on Ascelia Pharma AB stock, see the SE:ACE Stock Forecast page.
More about Ascelia Pharma AB
Ascelia Pharma AB is a Swedish biotech company specializing in orphan oncology treatments, developing and commercializing novel drugs that address unmet medical needs with defined development and market pathways. The company’s pipeline includes two drug candidates, Orviglance and Oncoral, and it is headquartered in Malmö with a listing on Nasdaq Stockholm under the ticker ACE.
Average Trading Volume: 1,142,618
Technical Sentiment Signal: Sell
Current Market Cap: SEK388.2M
See more insights into ACE stock on TipRanks’ Stock Analysis page.